New combo therapy shows promise for Hard-to-Treat thyroid cancer
NCT ID NCT02152995
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tested whether the drug trametinib can help radioactive iodine (RAI) work better in people with advanced thyroid cancer that has spread or come back. It included 34 adults whose cancer had a specific gene change (RAS mutation) or no changes in RAS or RAF genes. The goal was to see if trametinib could make cancer cells take up more iodine, potentially slowing tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.